Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456
LaTonya J. Hickson, Larissa Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, Michael D. Jensen, Qingyi Jia, Kyra L. Jordan, Todd A. Kellogg, Sundeep Khosla, Daniel M. Koerber, Anthony B. Lagnado, Donna K. Lawson, Nathan K. LeBrasseur, Lilach O. Lerman, Kathleen M. McDonald, Travis J. McKenzie, João F. Passos, Robert J. Pignolo, Tamar Pirtskhalava, Ishran M. Saadiq, Kalli K. Schaefer, Stephen C. Textor, Stella Victorelli, Tammie L. Volkman, Ailing Xue, Mark Wentworth, Erin O. Wissler Gerdes, David B. Allison, Stephanie Dickinson, Keisuke Ejima, Elizabeth J. Atkinson, Marc E. Lenburg, Yi Zhu, Tamar Tchkonia, James L. Kirkland
Abstract
In this article, a re-analysis of the raw data has been conducted, which means that some conclusions presented in the paper have changed. The authors have written a Corrigendum which is appended (Appendix 1). In the interests of transparency, they have included de-identified data from the original article in Appendix 2. Download .docx (.54 MB) Help with docx files Download .xlsx (.01 MB) Help with xlsx files Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease“Hit-and-run” treatment with senolytics, which in the case of D + Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans. Full-Text PDF Open Access